{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:33:36Z","timestamp":1789605216552,"version":"build-2803163510"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,6]],"date-time":"2022-07-06T00:00:00Z","timestamp":1657065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,6]],"date-time":"2022-07-06T00:00:00Z","timestamp":1657065600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medizinische Fakult\u00e4t Mannheim der Universit\u00e4t Heidelberg"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>To assess safety and tolerability of intraocularly applied cetuximab as epidermal growth factor receptor antibody, we conducted the experimental study which consisted of groups of adult rabbits (body weight: 2.4\u00a0kg) and young rabbits (body weight: 1.6\u00a0kg). All animals received three intravitreal injections of 0.5\u00a0mg cetuximab (Erbitux) (0.10\u00a0mL; 5\u00a0mg cetuximab\/mL) into their right eyes in 4-week intervals, while the contralateral eyes received intravitreal injections of Ringer's solution. All animals underwent regular ophthalmological examinations at baseline and two-week intervals. Four weeks after the last injection, the animals were sacrificed, and the eyes were enucleated, fixed and examined by light microscopy. The study included 10 adult rabbits (age: 18\u00a0weeks; range: 17\u201319\u00a0weeks) and 8 young rabbits (age: 8\u00a0weeks; range: 7\u201310\u00a0weeks). Biometric measurements of axial length, anterior chamber depth and lens thickness and intraocular pressure readings did not differ significantly (all <jats:italic>P<\/jats:italic>\u2009&gt;\u20090.05, Bonferroni corrected) between the right (study) eyes and the left (control) eyes, neither in the young nor in the adult rabbit group. Signs of intraocular inflammation or fundus peculiarities were not detected. Thickness of the outer nuclear layer, inner nuclear layer, combined outer and inner nuclear layer and outer plexiform layer, and total retina, measured at the posterior pole, posterior pole\/equator midpoint, equator, and ora serrata region, did not vary significantly between study eyes and control eyes (all <jats:italic>P<\/jats:italic>\u2009&gt;\u20090.05, Bonferroni corrected). The results suggest that repeated intravitreal application of cetuximab did not result in any detected intraocular toxic or destructive effect in young and adult rabbits, concurring with the notion of an intraocular tolerability of cetuximab.<\/jats:p>","DOI":"10.1038\/s41598-022-15642-4","type":"journal-article","created":{"date-parts":[[2022,7,6]],"date-time":"2022-07-06T20:06:58Z","timestamp":1657138018000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Safety and tolerability of intravitreal cetuximab in young and adult rabbits"],"prefix":"10.1038","volume":"12","author":[{"given":"Mukharram M.","family":"Bikbov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gyulli M.","family":"Kazakbaeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songhomitra","family":"Panda-Jonas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinar A.","family":"Khakimov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leisan I.","family":"Gilemzianova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liana A.","family":"Miniazeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azaliia M.","family":"Tuliakova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albina A.","family":"Fakhretdinova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renat A.","family":"Kazakbaev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ildar F.","family":"Nuriev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jost B.","family":"Jonas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,6]]},"reference":[{"key":"15642_CR1","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.ajo.2010.05.009","volume":"150","author":"N Saka","year":"2010","unstructured":"Saka, N. et al. Long-term changes in axial length in adult eyes with pathologic myopia. Am. J. Ophthalmol. 150, 562-568.e1 (2010).","journal-title":"Am. J. Ophthalmol."},{"key":"15642_CR2","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.ophtha.2017.12.005","volume":"125","author":"Y Fang","year":"2018","unstructured":"Fang, Y. et al. Progression of myopic maculopathy during 18-year follow-up. Ophthalmology 125, 863\u2013877 (2018).","journal-title":"Ophthalmology"},{"key":"15642_CR3","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1136\/bjophthalmol-2019-314619","volume":"104","author":"MW Lee","year":"2020","unstructured":"Lee, M. W., Lee, S. E., Lim, H. B. & Kim, J. Y. Longitudinal changes in axial length in high myopia: A 4-year prospective study. Br. J. Ophthalmol. 104, 600\u2013603 (2020).","journal-title":"Br. J. Ophthalmol."},{"key":"15642_CR4","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1001\/jamaophthalmol.2021.3303","volume":"139","author":"R Du","year":"2021","unstructured":"Du, R. et al. Continued increase of axial length and its risk factors in adults with high myopia. JAMA Ophthalmol. 139, 1096\u20131103 (2021).","journal-title":"JAMA Ophthalmol."},{"key":"15642_CR5","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1097\/IAE.0000000000001464","volume":"37","author":"JB Jonas","year":"2017","unstructured":"Jonas, J. B., Ohno-Matsui, K., Jiang, W. J. & Panda-Jonas, S. Bruch membrane and the mechanism of myopization. A new theory. Retina 37, 1428\u20131440 (2017).","journal-title":"Retina"},{"key":"15642_CR6","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.ebiom.2017.02.021","volume":"17","author":"WJ Jiang","year":"2017","unstructured":"Jiang, W. J. et al. Amphiregulin antibody and reduction of axial elongation in experimental myopia. EBioMedicine 17, 134\u2013144 (2017).","journal-title":"EBioMedicine"},{"key":"15642_CR7","doi-asserted-by":"publisher","first-page":"e460","DOI":"10.1111\/aos.14080","volume":"97","author":"L Dong","year":"2019","unstructured":"Dong, L. et al. Amphiregulin and ocular axial length. Acta Ophthalmol. 97, e460\u2013e470 (2019).","journal-title":"Acta Ophthalmol."},{"key":"15642_CR8","doi-asserted-by":"publisher","first-page":"13654","DOI":"10.1096\/fj.202001095RR","volume":"34","author":"L Dong","year":"2020","unstructured":"Dong, L. et al. Blockade of epidermal growth factor and its receptor and axial elongation in experimental myopia. FASEB J. 34, 13654\u201321367 (2020).","journal-title":"FASEB J."},{"key":"15642_CR9","doi-asserted-by":"publisher","first-page":"3229","DOI":"10.1007\/s00417-021-05200-5","volume":"259","author":"JB Jonas","year":"2021","unstructured":"Jonas, J. B. et al. Intraocular epidermal growth factor concentration, axial length, and high axial myopia. Graefes. Arch. Clin. Exp. Ophthalmol. 259, 3229\u20133234 (2021).","journal-title":"Graefes. Arch. Clin. Exp. Ophthalmol."},{"key":"15642_CR10","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1056\/NEJMoa033025","volume":"351","author":"D Cunningham","year":"2004","unstructured":"Cunningham, D. et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 351, 337\u2013345 (2004).","journal-title":"N. Engl. J. Med."},{"key":"15642_CR11","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1056\/NEJMoa0805019","volume":"360","author":"E Van Cutsem","year":"2009","unstructured":"Van Cutsem, E. et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N. Engl. J. Med. 360, 1408\u20131417 (2009).","journal-title":"N. Engl. J. Med."},{"key":"15642_CR12","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1007\/s10792-021-01761-w","volume":"41","author":"MM Bikbov","year":"2021","unstructured":"Bikbov, M. M. et al. Compatibility of intravitreally applied epidermal growth factor and amphiregulin. Int. Ophthalmol. 41, 2053\u20132063 (2021).","journal-title":"Int. Ophthalmol."},{"key":"15642_CR13","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1053\/j.seminoncol.2006.04.003","volume":"33","author":"J Mendelsohn","year":"2006","unstructured":"Mendelsohn, J. & Baselga, J. Epidermal growth factor receptor targeting in cancer. Semin. Oncol. 33, 369\u2013385 (2006).","journal-title":"Semin. Oncol."},{"key":"15642_CR14","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1093\/annonc\/mdi279","volume":"16","author":"S Segaert","year":"2005","unstructured":"Segaert, S. & Van Cutsem, E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann. Oncol. 16, 1425\u20131433 (2005).","journal-title":"Ann. Oncol."},{"key":"15642_CR15","unstructured":"https:\/\/www.medicines.org.uk\/emc\/product\/317\/smpc#gref. Assessed 25.2.2022"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-15642-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-15642-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-15642-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T06:25:39Z","timestamp":1669357539000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-15642-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,6]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["15642"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-15642-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,6]]},"assertion":[{"value":"25 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Jost B. Jonas, Songhomitra Panda-Jonas: European patent EP 3 271 392, JP 2021-119187, and US 2021 0340237 A1: Agents for use in the therapeutic or prophylactic treatment of myopia or hyperopia; Patent application: European patent application: WO 2021\/198369 A1; PCT\/EP2021\/058500: Agents for the use in the therapeutic or prophylactic treatment of retinal pigment epithelium associated diseases. All other authors: None.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"11454"}}